|
【结 构 式】 
|
【药物名称】CGP-7040 【化学名称】3-[4-(2,4,6-Trimethylbenzyl)piperazin-1-yl]rifamycin SV 【CA登记号】109006-01-1 【 分 子 式 】C51H67N3O12 【 分 子 量 】914.11554 |
【开发单位】Novartis (Originator) 【药理作用】AIDS Medicines, ANTIINFECTIVE THERAPY, Macrolides |
合成路线1
This compound has been obtained by two related ways: 1. By direct condensation of rifamycin S (I) with 1-(2,4,6-trimethylphenyl)piperazine (II), followed by reduction of the quinone subunit to the target hydroquinone with sodium ascorbate. 2. The bromination of rifamycin S (I) with Br2/pyridine in DMF gives 3-bromorifamycin S (III), which is condensed with piperazine (II) and reduced to the target hydroquinone as before.
| 【1】 Vischer, W.; Traxler, P.; Kump, W.; Costa-Pereira, R.; Gowrishankar, R.; Zak, O.; Lydon, N.; Ashtekar, D.R.; Batt, E.; Tosch, W.; 3-Alkylbenzylpiperazinyl-rifamycins: New rifamycins with long plasma half-lives, high activity aganist Micobacterium avium complex (MAC) and reverse transcription. 27th Intersci Conf Antimicrob Agents Chemother 1987, Abst 275. |
| 【2】 (Novartis AG); Process for the preparation of a peptide derivative of the lysergic acid. CH 282603 . |
| 【3】 Traxler, P.; Vischer, W.; Zak, O.; New Rifamycins. Drugs Fut 1988, 13, 9, 845. |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (I) | 31943 | Rifamycin S; (7S,11S,12R,13S,14R,15R,16R,17S,18S)-2,15,17-trihydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23,27,29-tetraoxo-8,30-dioxa-24-azatetracyclo[23.3.1.1(4,7).0(5,28)]triaconta-1(28),2,4,9,19,21,25-heptaen-13-yl acetate | C37H45NO12 | 详情 | 详情 | |
| (II) | 43687 | 1-(mesitylmethyl)piperazine | C14H22N2 | 详情 | 详情 | |
| (III) | 31944 | (7S,11S,12R,13S,14R,15R,16R,17S,18S)-26-bromo-2,15,17-trihydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23,27,29-tetraoxo-8,30-dioxa-24-azatetracyclo[23.3.1.1(4,7).0(5,28)]triaconta-1(28),2,4,9,19,21,25-heptaen-13-yl acetate; 3-bromorifamicin S | C37H44BrNO12 | 详情 | 详情 |
Extended Information